Hwaseong-si, South Korea

Soo-Jin Lee

USPTO Granted Patents = 2 

Average Co-Inventor Count = 9.9

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Inventor Soo-Jin Lee

Introduction

Soo-Jin Lee is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of innovative compounds. With a total of 2 patents to his name, his work focuses on advancing medical treatments through novel chemical compounds.

Latest Patents

Soo-Jin Lee's latest patents include groundbreaking research on autotaxin inhibitor compounds. The present disclosure provides autotaxin (ATX) inhibitor compounds and compositions that include these compounds. It also outlines methods for using these compounds and compositions to inhibit ATX, along with methods for preparing these compounds and their synthetic precursors. Another significant patent involves substituted pyrazolo[4,3-d]pyrimidines and imidazo[5,1-f][1,2,4]triazines as dual inhibitors of androgen receptors and phosphodiesterase 5 (PDE-5). This patent details compounds that can inhibit both AR and PDE-5, providing dual functionality in biological systems.

Career Highlights

Soo-Jin Lee is currently associated with Il Dong Pharmaceutical Co., Ltd., where he continues to innovate and develop new pharmaceutical solutions. His work is characterized by a commitment to enhancing therapeutic options for various medical conditions.

Collaborations

Some of his notable coworkers include Jeong-Ah Kim and Jun-Su Ban, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Soo-Jin Lee's contributions to the field of pharmaceuticals through his innovative patents highlight his role as a key inventor in advancing medical science. His work continues to pave the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…